Saturn V Capital Management LP Reports New 5.2% Stake in Monopar Therapeutics Inc.

On May 15, 2026, Saturn V Capital Management LP and Xiaoying Tian filed a Schedule 13G regarding their holdings in Monopar Therapeutics Inc. (MNPR). The filing reveals that the reporting persons have acquired a 5.2% ownership stake in the company, representing 345,626 shares of common stock. This position was established as of the event date of January 5, 2026. Saturn V Capital Management LP serves as the investment manager for various clients and pooled investment vehicles, granting it shared voting and dispositive power over the shares. Xiaoying Tian, as the Managing Member of SVCM GP LLC (the general partner of Saturn V), is also identified as a reporting person with shared power over the holdings. Both reporting persons disclaim beneficial ownership of the shares held by their clients. The calculation of the ownership percentage is based on 6,698,778 shares outstanding as of April 27, 2026. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of influencing control of the issuer.